After 25 years, Hovione's CEO will step down; Helsinn gains infigratinib license from BridgeBio
Hovione’s current COO will become its CEO on April 1.
The company announced that Guy Villax, the CEO for 25 years, will step down from his role. He will transition to the role of board member and shareholder. The company grew 10-fold in his tenure, growing to 2,000 team members and four production sites in the US, China, Portugal and Ireland.
“It has been a privilege and honor to lead Hovione over the last decades. Hovione is a great company because of its people and its clients. It has been an amazing entrepreneurial and human journey with so many projects and unforgettable success stories. I have seen this company, founded by my parents, growing, evolving and constantly re-inventing itself,” Villax said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.